Details of the Drug

General Information of Drug (ID: DM5L6HI)

Drug Name
Atomoxetine
Synonyms
Tomoxetina; Tomoxetine; Tomoxetinum; Tomoxetina [Spanish]; Tomoxetine [INN]; Tomoxetinum [Latin]; Atomoxetine (INN); Attentin (TN); Strattera (TN); Tomoxetin (TN); (-)-Tomoxetine; (3R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine
Indication
Disease Entry ICD 11 Status REF
Attention deficit hyperactivity disorder 6A05.Z Approved [1], [2]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 255.35
Topological Polar Surface Area (xlogp) 3.7
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 2
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 2 mgh/L [3]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 350 mcg/L [3]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 1-2 h [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Bioavailability
The bioavailability of drug is 63% [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 9.3 mL/min/kg [5]
Elimination
Atomoxetine is excreted primarily as 4-hydroxyatomoxetine-O-glucuronide, mainly in the urine (greater than 80% of the dose) and to a lesser extent in the feces (less than 17% of the dose) [6]
Half-life
The concentration or amount of drug in body reduced by one-half in 3 - 5.6 hours [3]
Metabolism
The drug is metabolized via several other cytochrome P450 enzymes [7]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 8.3915 micromolar/kg/day [8]
Unbound Fraction
The unbound fraction of drug in plasma is 0.02% [5]
Vd
The volume of distribution (Vd) of drug is 1.6-2.6 L/kg [3]
Water Solubility
The ability of drug to dissolve in water is measured as 27.8 mg/mL [4]
Chemical Identifiers
Formula
C17H21NO
IUPAC Name
(3R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine
Canonical SMILES
CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2
InChI
InChI=1S/C17H21NO/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15/h3-11,17-18H,12-13H2,1-2H3/t17-/m1/s1
InChIKey
VHGCDTVCOLNTBX-QGZVFWFLSA-N
Cross-matching ID
PubChem CID
54841
ChEBI ID
CHEBI:127342
CAS Number
83015-26-3
DrugBank ID
DB00289
TTD ID
D04CRN
VARIDT ID
DR00393
INTEDE ID
DR0153
ACDINA ID
D00049

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Norepinephrine transporter (NET) TTAWNKZ SC6A2_HUMAN Inhibitor [9], [10]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [11]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2D6 (CYP2D6)
Main DME 		DECB0K3 CP2D6_HUMAN Substrate [12]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [12]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Attention deficit hyperactivity disorder
ICD Disease Classification 6A05.Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Norepinephrine transporter (NET) DTT SLC6A2 7.05E-01 7.02E-03 0.07
P-glycoprotein 1 (ABCB1) DTP P-GP 7.83E-01 4.69E-02 1.89E-01
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 7.66E-01 9.19E-03 4.88E-02
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 5.64E-01 2.36E-02 1.75E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Atomoxetine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [48]
Coadministration of a Drug Treating the Disease Different from Atomoxetine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Atomoxetine and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [49]
Methylene blue DMJAPE7 Major Increased risk of hyperpyrexia by the combination of Atomoxetine and Methylene blue. Acquired methaemoglobinaemia [3A93] [50]
Thioguanine DM7NKEV Moderate Increased risk of hepatotoxicity by the combination of Atomoxetine and Thioguanine. Acute myeloid leukaemia [2A60] [51]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Atomoxetine and Ivosidenib. Acute myeloid leukaemia [2A60] [52]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Midostaurin. Acute myeloid leukaemia [2A60] [53]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Idarubicin. Acute myeloid leukaemia [2A60] [53]
Daunorubicin DMQUSBT Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Daunorubicin. Acute myeloid leukaemia [2A60] [53]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Arn-509. Acute myeloid leukaemia [2A60] [48]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Oliceridine. Acute pain [MG31] [53]
Terfenadine DM4KLPT Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Terfenadine. Allergic/hypersensitivity disorder [4A80-4A8Z] [53]
Galantamine DMEO794 Moderate Increased risk of ventricular arrhythmias by the combination of Atomoxetine and Galantamine. Alzheimer disease [8A20] [53]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Atomoxetine and Rivastigmine. Alzheimer disease [8A20] [53]
Donepezil DMIYG7Z Moderate Increased risk of ventricular arrhythmias by the combination of Atomoxetine and Donepezil. Alzheimer disease [8A20] [53]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Atomoxetine and Metronidazole. Amoebiasis [1A36] [49]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Atomoxetine and Ivabradine. Angina pectoris [BA40] [48]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Atomoxetine and Dronedarone. Angina pectoris [BA40] [53]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Atomoxetine and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [54]
Hydroxyzine DMF8Y74 Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [53]
Clobazam - Lundbeck DMW1OQ0 Moderate Decreased metabolism of Atomoxetine caused by Clobazam - Lundbeck mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [55]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Cilostazol. Arterial occlusive disease [BD40] [53]
Voriconazole DMAOL2S Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Voriconazole. Aspergillosis [1F20] [53]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Posaconazole. Aspergillosis [1F20] [53]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Ofloxacin. Bacterial infection [1A00-1C4Z] [56]
Ciprofloxacin XR DM2NLS9 Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [53]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Clarithromycin. Bacterial infection [1A00-1C4Z] [53]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Atomoxetine and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [53]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Atomoxetine and Sparfloxacin. Bacterial infection [1A00-1C4Z] [56]
Linezolid DMGFPU2 Major Additive hypertensive effects by the combination of Atomoxetine and Linezolid. Bacterial infection [1A00-1C4Z] [50]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Levofloxacin. Bacterial infection [1A00-1C4Z] [56]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Lomefloxacin. Bacterial infection [1A00-1C4Z] [53]
Telithromycin DMZ4P3A Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Telithromycin. Bacterial infection [1A00-1C4Z] [53]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Retigabine. Behcet disease [4A62] [53]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Atomoxetine and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [57]
Loperamide DMOJZQ9 Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Loperamide. Bowel habit change [ME05] [58]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Eribulin. Breast cancer [2C60-2C6Y] [53]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Lapatinib. Breast cancer [2C60-2C6Y] [53]
Tamoxifen DMLB0EZ Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Tamoxifen. Breast cancer [2C60-2C6Y] [53]
Toremifene DMQYUWG Major Increased risk of prolong QT interval by the combination of Atomoxetine and Toremifene. Breast cancer [2C60-2C6Y] [53]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Bosutinib. Breast cancer [2C60-2C6Y] [48]
Grepafloxacin DMGLX0T Major Increased risk of prolong QT interval by the combination of Atomoxetine and Grepafloxacin. Bronchitis [CA20] [56]
Sotalol DML60TN Major Increased risk of prolong QT interval by the combination of Atomoxetine and Sotalol. Cardiac arrhythmia [BC9Z] [53]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [59]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Halothane. Corneal disease [9A76-9A78] [53]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Propofol. Corneal disease [9A76-9A78] [60]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Probucol. Coronary atherosclerosis [BA80] [53]
Methadone DMTW6IU Major Increased risk of prolong QT interval by the combination of Atomoxetine and Methadone. Cough [MD12] [53]
Clofazimine DMEBOFW Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Clofazimine. Crohn disease [DD70] [61]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Atomoxetine and Mifepristone. Cushing syndrome [5A70] [53]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Atomoxetine and Pasireotide. Cushing syndrome [5A70] [53]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Osilodrostat. Cushing syndrome [5A70] [48]
Sertraline DM0FB1J Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Sertraline. Depression [6A70-6A7Z] [53]
Fluoxetine DM3PD2C Major Decreased metabolism of Atomoxetine caused by Fluoxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [55]
Paroxetine DM5PVQE Major Decreased metabolism of Atomoxetine caused by Paroxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [55]
Selegiline DM6034S Major Additive hypertensive effects by the combination of Atomoxetine and Selegiline. Depression [6A70-6A7Z] [50]
Duloxetine DM9BI7M Moderate Decreased metabolism of Atomoxetine caused by Duloxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [55]
Isocarboxazid DMAF1NB Major Additive hypertensive effects by the combination of Atomoxetine and Isocarboxazid. Depression [6A70-6A7Z] [50]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Atomoxetine and Escitalopram. Depression [6A70-6A7Z] [53]
Tranylcypromine DMGB5RE Major Additive hypertensive effects by the combination of Atomoxetine and Tranylcypromine. Depression [6A70-6A7Z] [50]
Phenelzine DMHIDUE Major Increased risk of hyperpyrexia by the combination of Atomoxetine and Phenelzine. Depression [6A70-6A7Z] [50]
Clomipramine DMINRKW Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Clomipramine. Depression [6A70-6A7Z] [53]
Mirtazapine DML53ZJ Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Mirtazapine. Depression [6A70-6A7Z] [62]
Esketamine DMVU687 Major Additive hypertensive effects by the combination of Atomoxetine and Esketamine. Depression [6A70-6A7Z] [49]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [53]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Deutetrabenazine. Dystonic disorder [8A02] [63]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Ingrezza. Dystonic disorder [8A02] [64]
Stiripentol DMMSDOY Moderate Decreased metabolism of Atomoxetine caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [55]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Atomoxetine and Cannabidiol. Epileptic encephalopathy [8A62] [48]
Diphenhydramine DMKQTBA Moderate Decreased metabolism of Atomoxetine caused by Diphenhydramine mediated inhibition of CYP450 enzyme. Episodic vestibular syndrome [AB31] [55]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Solifenacin. Functional bladder disorder [GC50] [53]
Mirabegron DMS1GYT Moderate Decreased metabolism of Atomoxetine caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [55]
Darifenacin DMWXLYZ Moderate Decreased metabolism of Atomoxetine caused by Darifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [55]
Pentamidine DMHZJCG Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Pentamidine. Fungal infection [1F29-1F2F] [53]
Terbinafine DMI6HUW Moderate Decreased metabolism of Atomoxetine caused by Terbinafine mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [55]
Ketoconazole DMPZI3Q Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Ketoconazole. Fungal infection [1F29-1F2F] [53]
Cimetidine DMH61ZB Moderate Decreased metabolism of Atomoxetine caused by Cimetidine mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [55]
Cisapride DMY7PED Major Increased risk of prolong QT interval by the combination of Atomoxetine and Cisapride. Gastro-oesophageal reflux disease [DA22] [53]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Sunitinib. Gastrointestinal stromal tumour [2B5B] [53]
Procarbazine DMIK367 Major Increased risk of hyperpyrexia by the combination of Atomoxetine and Procarbazine. Hodgkin lymphoma [2B30] [50]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Atomoxetine and Brentuximab vedotin. Hodgkin lymphoma [2B30] [65]
Delavirdine DM3NF5G Moderate Decreased metabolism of Atomoxetine caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [55]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [66]
Cobicistat DM6L4H2 Moderate Decreased clearance of Atomoxetine due to the transporter inhibition by Cobicistat. Human immunodeficiency virus disease [1C60-1C62] [67]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Atomoxetine and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [68]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [53]
Ritonavir DMU764S Moderate Decreased metabolism of Atomoxetine caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [55]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Atomoxetine and Mipomersen. Hyper-lipoproteinaemia [5C80] [69]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Atomoxetine and Teriflunomide. Hyper-lipoproteinaemia [5C80] [53]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Atomoxetine and BMS-201038. Hyper-lipoproteinaemia [5C80] [70]
Cinacalcet DMCX0K3 Major Decreased metabolism of Atomoxetine caused by Cinacalcet mediated inhibition of CYP450 enzyme. Hyper-parathyroidism [5A51] [55]
Givosiran DM5PFIJ Moderate Decreased metabolism of Atomoxetine caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [55]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Atomoxetine and Polyethylene glycol. Irritable bowel syndrome [DD91] [53]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Atomoxetine and Phenolphthalein. Irritable bowel syndrome [DD91] [53]
Methotrexate DM2TEOL Moderate Increased risk of hepatotoxicity by the combination of Atomoxetine and Methotrexate. Leukaemia [2A60-2B33] [48]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Atomoxetine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [55]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Atomoxetine and Crizotinib. Lung cancer [2C25] [71]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Atomoxetine and Ceritinib. Lung cancer [2C25] [53]
Dacomitinib DMOH8VY Major Decreased metabolism of Atomoxetine caused by Dacomitinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [55]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Atomoxetine and Osimertinib. Lung cancer [2C25] [72]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Atomoxetine and Selpercatinib. Lung cancer [2C25] [48]
Lumefantrine DM29GAD Moderate Decreased metabolism of Atomoxetine caused by Lumefantrine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [49]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Atomoxetine and Halofantrine. Malaria [1F40-1F45] [73]
Chloroquine DMSI5CB Major Increased risk of prolong QT interval by the combination of Atomoxetine and Chloroquine. Malaria [1F40-1F45] [74]
Quinine DMSWYF5 Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Quinine. Malaria [1F40-1F45] [53]
Primaquine DMWQ16I Moderate Decreased metabolism of Atomoxetine caused by Primaquine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [55]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Atomoxetine and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [75]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Atomoxetine and Idelalisib. Mature B-cell leukaemia [2A82] [76]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Atomoxetine and Arsenic trioxide. Mature B-cell lymphoma [2A85] [77]
Clofarabine DMCVJ86 Moderate Increased risk of hepatotoxicity by the combination of Atomoxetine and Clofarabine. Mature B-cell lymphoma [2A85] [78]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Atomoxetine and Vemurafenib. Melanoma [2C30] [53]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Atomoxetine and Panobinostat. Multiple myeloma [2A83] [79]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Atomoxetine and Thalidomide. Multiple myeloma [2A83] [49]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Atomoxetine and Siponimod. Multiple sclerosis [8A40] [49]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Atomoxetine and Fingolimod. Multiple sclerosis [8A40] [53]
Ozanimod DMT6AM2 Major Increased risk of hyperpyrexia by the combination of Atomoxetine and Ozanimod. Multiple sclerosis [8A40] [50]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Romidepsin. Mycosis fungoides [2B01] [53]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Atomoxetine caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [55]
Imatinib DM7RJXL Moderate Decreased metabolism of Atomoxetine caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [55]
Droperidol DM0DXA8 Major Increased risk of prolong QT interval by the combination of Atomoxetine and Droperidol. Nausea/vomiting [MD90] [53]
Prochlorperazine DM53SRA Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Prochlorperazine. Nausea/vomiting [MD90] [53]
Promethazine DM6I5GR Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Promethazine. Nausea/vomiting [MD90] [53]
Rolapitant DM8XP26 Moderate Decreased metabolism of Atomoxetine caused by Rolapitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [80]
Palonosetron DMBHMOX Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Palonosetron. Nausea/vomiting [MD90] [53]
Granisetron DMIUW25 Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Granisetron. Nausea/vomiting [MD90] [53]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Atomoxetine and Dolasetron. Nausea/vomiting [MD90] [53]
Ondansetron DMOTQ1I Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Ondansetron. Nausea/vomiting [MD90] [53]
Bupropion DM5PCS7 Moderate Decreased metabolism of Atomoxetine caused by Bupropion mediated inhibition of CYP450 enzyme. Nicotine use disorder [6C4A] [55]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Entrectinib. Non-small cell lung cancer [2C25] [49]
Lorcaserin DMG6OYJ Moderate Decreased metabolism of Atomoxetine caused by Lorcaserin mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [55]
Dexfenfluramine DMJ7YDS Moderate Decreased metabolism of Atomoxetine caused by Dexfenfluramine mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [55]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Lofexidine. Opioid use disorder [6C43] [53]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Rucaparib. Ovarian cancer [2C73] [53]
Dextropropoxyphene DM23HCX Moderate Decreased metabolism of Atomoxetine caused by Dextropropoxyphene mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [55]
Buprenorphine DMPRI8G Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Buprenorphine. Pain [MG30-MG3Z] [53]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Triclabendazole. Parasitic worm infestation [1F90] [53]
Safinamide DM0YWJC Moderate Decreased metabolism of Atomoxetine caused by Safinamide mediated inhibition of non-CYP450 enzyme. Parkinsonism [8A00] [81]
Rasagiline DM3WKQ4 Moderate Additive hypertensive effects by the combination of Atomoxetine and Rasagiline. Parkinsonism [8A00] [50]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Pimavanserin. Parkinsonism [8A00] [82]
Apomorphine DMX38HQ Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Apomorphine. Parkinsonism [8A00] [53]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Atomoxetine and Macimorelin. Pituitary gland disorder [5A60-5A61] [83]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Atomoxetine and Lefamulin. Pneumonia [CA40] [84]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Degarelix. Prostate cancer [2C82] [48]
ABIRATERONE DM8V75C Moderate Decreased metabolism of Atomoxetine caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [55]
Nilutamide DMFN07X Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Nilutamide. Prostate cancer [2C82] [48]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Enzalutamide. Prostate cancer [2C82] [48]
Flutamide DMK0O7U Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Flutamide. Prostate cancer [2C82] [48]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Bicalutamide. Prostate cancer [2C82] [48]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Levomepromazine. Psychotic disorder [6A20-6A25] [53]
Fluphenazine DMIT8LX Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Fluphenazine. Psychotic disorder [6A20-6A25] [53]
Triflupromazine DMKFQJP Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Triflupromazine. Psychotic disorder [6A20-6A25] [53]
Sorafenib DMS8IFC Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Sorafenib. Renal cell carcinoma [2C90] [53]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Atomoxetine and Gatifloxacin. Respiratory infection [CA07-CA4Z] [85]
Celecoxib DM6LOQU Moderate Decreased metabolism of Atomoxetine caused by Celecoxib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [55]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Atomoxetine and Leflunomide. Rheumatoid arthritis [FA20] [53]
Oxamniquine DM2QDX1 Moderate Decreased metabolism of Atomoxetine caused by Oxamniquine mediated inhibition of CYP450 enzyme. Schistosomiasis [1F86] [55]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Atomoxetine and Mesoridazine. Schizophrenia [6A20] [53]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Atomoxetine and Thioridazine. Schizophrenia [6A20] [53]
Aripiprazole DM3NUMH Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Aripiprazole. Schizophrenia [6A20] [49]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Atomoxetine and Iloperidone. Schizophrenia [6A20] [53]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Paliperidone. Schizophrenia [6A20] [53]
Haloperidol DM96SE0 Major Increased risk of prolong QT interval by the combination of Atomoxetine and Haloperidol. Schizophrenia [6A20] [53]
Perphenazine DMA4MRX Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Perphenazine. Schizophrenia [6A20] [53]
Chlorpromazine DMBGZI3 Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Chlorpromazine. Schizophrenia [6A20] [53]
Clozapine DMFC71L Major Increased risk of prolong QT interval by the combination of Atomoxetine and Clozapine. Schizophrenia [6A20] [53]
Trifluoperazine DMKBYWI Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Trifluoperazine. Schizophrenia [6A20] [53]
Risperidone DMN6DXL Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Risperidone. Schizophrenia [6A20] [53]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Atomoxetine and Amisulpride. Schizophrenia [6A20] [86]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Asenapine. Schizophrenia [6A20] [53]
Vardenafil DMTBGW8 Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Vardenafil. Sexual dysfunction [HA00-HA01] [53]
Gefitinib DM15F0X Moderate Decreased metabolism of Atomoxetine caused by Gefitinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [55]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Atomoxetine and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [48]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Atomoxetine and LEE011. Solid tumour/cancer [2A00-2F9Z] [53]
Epirubicin DMPDW6T Moderate Increased risk of hepatotoxicity by the combination of Atomoxetine and Epirubicin. Solid tumour/cancer [2A00-2F9Z] [49]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Atomoxetine and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [53]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [48]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [53]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Pitolisant. Somnolence [MG42] [53]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [53]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Atomoxetine and Naltrexone. Substance abuse [6C40] [87]
Ibutilide DMKXY2R Major Increased risk of prolong QT interval by the combination of Atomoxetine and Ibutilide. Supraventricular tachyarrhythmia [BC81] [53]
Adenosine DMM2NSK Moderate Increased risk of ventricular arrhythmias by the combination of Atomoxetine and Adenosine. Supraventricular tachyarrhythmia [BC81] [53]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Lenvatinib. Thyroid cancer [2D10] [53]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Atomoxetine and Cabozantinib. Thyroid cancer [2D10] [48]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Atomoxetine and Papaverine. Tonus and reflex abnormality [MB47] [88]
Tizanidine DMR2IQ4 Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Tizanidine. Tonus and reflex abnormality [MB47] [53]
Tacrolimus DMZ7XNQ Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Tacrolimus. Transplant rejection [NE84] [53]
Astemizole DM2HN6Q Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Astemizole. Vasomotor/allergic rhinitis [CA08] [53]
Trimeprazine DMEMV9D Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [89]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Atomoxetine and Procainamide. Ventricular tachyarrhythmia [BC71] [53]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Atomoxetine and Propafenone. Ventricular tachyarrhythmia [BC71] [53]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Atomoxetine and Amiodarone. Ventricular tachyarrhythmia [BC71] [53]
⏷ Show the Full List of 190 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
D&C red no. 28 E00491 6097185 Colorant
D&C red no. 33 E00261 19116 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Isopropyl alcohol E00070 3776 Antimicrobial preservative; Solvent
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF E00255 17730 Colorant
Ammonia E00007 222 Alkalizing agent
Butyl alcohol E00011 263 Flavoring agent; Solvent
Eisenoxyd E00585 56841934 Colorant
FD&C red no. 3 E00629 Not Available Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Magnesium stearate E00208 11177 lubricant
Potassium hydroxide E00233 14797 Alkalizing agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 20 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Atomoxetine 60 mg capsule 60 mg Oral Capsule Oral
Atomoxetine 18 mg capsule 18 mg Oral Capsule Oral
Atomoxetine 25 mg capsule 25 mg Oral Capsule Oral
Atomoxetine 40 mg capsule 40 mg Oral Capsule Oral
Atomoxetine 100 mg capsule 100 mg Oral Capsule Oral
Atomoxetine 80 mg capsule 80 mg Oral Capsule Oral
Atomoxetine 10 mg capsule 10 mg Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7118).
2 Anti-obesity drugs and neural circuits of feeding. Trends Pharmacol Sci. 2008 Apr;29(4):208-17.
3 Atomoxetine: A Review of Its Pharmacokinetics and Pharmacogenomics Relative to Drug Disposition. J Child Adolesc Psychopharmacol. 2016 May;26(4):314-26. doi: 10.1089/cap.2015.0137. Epub 2016 Feb 9.
4 BDDCS applied to over 900 drugs
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
7 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
8 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9 Atomoxetine reverses attentional deficits produced by noradrenergic deafferentation of medial prefrontal cortex. Psychopharmacology (Berl). 2008 Sep;200(1):39-50.
10 New drugs for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Emerg Drugs. 2004 Nov;9(2):293-302.
11 Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
12 Atomoxetine: a review of its pharmacokinetics and pharmacogenomics relative to drug disposition. J Child Adolesc Psychopharmacol. 2016 May;26(4):314-26.
13 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
14 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
15 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
16 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
17 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
18 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
19 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
20 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
21 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
22 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
23 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
24 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
25 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
26 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
27 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
28 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
29 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
30 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
31 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
32 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
33 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
34 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
35 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
36 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
37 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
38 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
39 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
40 Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
41 Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
42 Invivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):220-8.
43 Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
44 Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
45 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
46 Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90.
47 Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42.
48 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
49 Cerner Multum, Inc. "Australian Product Information.".
50 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
51 Product Information. Aubagio (teriflunomide). Genzyme Corporation, Cambridge, MA.
52 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
53 Canadian Pharmacists Association.
54 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
55 Belle DJ, Ernest CS, Sauer JM, Smith BP, Thomasson HR, Witcher JW "Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics." J Clin Pharmacol 42 (2002): 1219-27. [PMID: 12412820]
56 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
57 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
58 Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
59 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
60 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
61 Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
62 Product Information. Remeron (mirtazapine). Organon, West Orange, NJ.
63 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
64 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
65 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
66 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
67 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
68 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
69 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
70 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
71 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
72 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
73 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
74 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
75 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
76 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
77 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
78 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
79 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
80 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
81 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
82 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
83 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
84 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
85 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
86 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
87 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
88 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
89 Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]